



ORAL PRESENTATION

Open Access

O125. Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients

H Valdez^{1*}, D Chapman¹, P Biswai², M Lewis³, C Craig³, J Heera⁴, S Ellery⁴, LC Swenson⁵, PR Harrigan⁵*From* Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010**Background**

Both population and ultra-deep sequencing (UDS) of the HIV-1 V3 loop are useful in selecting candidates for maraviroc (MVC) therapy. We used mathematical modeling to determine that patients whose non-R5 HIV comprises <2% of the viral population by UDS are likely to respond to a MVC-containing regimen. However, the predictive value of absolute amount of non-R5 HIV is unknown.

Objective

To determine whether non-R5 viral load contributes to predicting response to a MVC-containing regimen.

Methods

Patients enrolled in the MERIT study (MVC or efavirenz plus zidovudine/lamivudine in treatment-naïve patients) with R5 virus at screening (by original Trofile assay) and randomized to the twice-daily MVC arm were included. UDS was performed with a 454/Roche GS-FLX instrument. Tropism was predicted using the "geno2pheno" co-receptor algorithm (g2p). A sample was considered R5 if <2% of variants had a score below 3.5 FPR. MVC responses at Week 48 were predicted by descriptive statistics and mathematical modeling.

Results

Samples for 343 patients (308 R5, 35 non-R5) were available. Baseline median CD4 and mean viral load (VL) were 247 and 232 cells/ μ L and 4.9 and 4.6 log₁₀ c/

mL in patients with R5 and non-R5 virus. No CXCR4-using viruses were detected in 249/343 (73%) patients. Among the 94 patients with detectable CXCR4-use, median (q25, q75) percent and absolute levels of CXCR4-using viruses were 0.8% (0.4-8.1) and 2.9 (2.3-3.5) log₁₀ c/mL, respectively. Week 48 virologic responses are shown in Table 1.

In univariate models, baseline CD4 and percent of CXCR4-using virus were not significant predictors of week 48 response ($p=0.12$; $p=0.26$); VL and absolute amount of CXCR4-using virus were significant ($p=0.02$; $p=0.03$) and were included in the multivariate model ($p=0.02$ for both in final model).

Conclusion

In MVC-treated patients in the MERIT study, baseline VL and absolute amount of CXCR4-using virus were predictive of Week 48 response. It is possible that total

Table 1

Baseline level of CXCR4-using virus	<50 HIV-1 RNA c/mL at Week 48, n/N (%)
Percentage	
<2%	207/308 (67.2)
2%—<10%	7/13 (53.8)
≤10%	11/22 (50.0)
Amount (log ₁₀ copies/mL)	
<1.0	171/251 (68.1)
1.0—<2.0	12/15 (80.0)
2.0—<3.0	23/36 (63.9)
3.0—<4.0	13/25 (52.0)
≤4.0	6/16 (37.5)

¹Pfizer Inc, New York, USA

Full list of author information is available at the end of the article

burden of CXCR4-using virus in drug-naïve individuals may play a greater role than the percentage of such virus in predicting response to regimens containing a CCR5 antagonist.

Author details

¹Pfizer Inc, New York, USA. ²Pfizer Inc, Collegeville, USA. ³Pfizer Global Research and Development, Sandwich, UK. ⁴Pfizer Global Research and Development, New London, USA. ⁵BC Centre for Excellence in HIV/AIDS, Vancouver, Canada.

Published: 8 November 2010

doi:10.1186/1758-2652-13-S4-O11

Cite this article as: Valdez *et al.*: O125. Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients. *Journal of the International AIDS Society* 2010 **13**(Suppl 4):O11.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

